BACKGROUND: Cholangiocarcinoma is the second most frequent primitive liver malignancy and is responsible for 3% of the malignant gastrointestinal neoplasms. The aims of this study were to determine the association of serum levels of CA 19-9 at diagnosis with other clinical data and serum liver function tests and to identify possible factors that influence the survival rates during follow-up. METHODS: Retrospective observational study of 89 patients with a diagnosis of cholangiocarcinoma followed at the Department of Gastroenterology during 5 years. Statistical analyses were performed using SPSS version 20.0. RESULTS: Patients were followed up for a median time of 127 days (IQR: 48-564), and the median age at diagnosis was 71.0 years (IQR: 62.0-77.5). The median survival rate was 14.0 months (IQR: 4.3-23.7), and the mortality rate was 79%. Patients with CA 19-9 levels ≥103 U/L had lower albumin levels and higher levels of alanine aminotransferase and γ-glutamyltransferase. CA 19-9 levels ≥103 U/L were associated with a higher probability of metastization (p = 0.001) and lower rates of treatment with curative intent (p = 0.024). In a multivariate analysis, CA 19-9 levels <103 U/L and surgery were independent predictors of survival. CONCLUSION: Predictive factors for overall survival were identified, namely presence of metastasis, surgery, and chemotherapy. CA 19-9 levels ≥103 U/L were predictive factors for survival and metastization.
BACKGROUND:Cholangiocarcinoma is the second most frequent primitive liver malignancy and is responsible for 3% of the malignant gastrointestinal neoplasms. The aims of this study were to determine the association of serum levels of CA 19-9 at diagnosis with other clinical data and serum liver function tests and to identify possible factors that influence the survival rates during follow-up. METHODS: Retrospective observational study of 89 patients with a diagnosis of cholangiocarcinoma followed at the Department of Gastroenterology during 5 years. Statistical analyses were performed using SPSS version 20.0. RESULTS:Patients were followed up for a median time of 127 days (IQR: 48-564), and the median age at diagnosis was 71.0 years (IQR: 62.0-77.5). The median survival rate was 14.0 months (IQR: 4.3-23.7), and the mortality rate was 79%. Patients with CA 19-9 levels ≥103 U/L had lower albumin levels and higher levels of alanine aminotransferase and γ-glutamyltransferase. CA 19-9 levels ≥103 U/L were associated with a higher probability of metastization (p = 0.001) and lower rates of treatment with curative intent (p = 0.024). In a multivariate analysis, CA 19-9 levels <103 U/L and surgery were independent predictors of survival. CONCLUSION: Predictive factors for overall survival were identified, namely presence of metastasis, surgery, and chemotherapy. CA 19-9 levels ≥103 U/L were predictive factors for survival and metastization.
Entities:
Keywords:
CA 19-9 antigen; Cholangiocarcinoma; Prognosis; Tumor biomarkers
Authors: R Hultcrantz; R Olsson; A Danielsson; G Järnerot; L Lööf; B O Ryden; B Wahren; U Broomé Journal: J Hepatol Date: 1999-04 Impact factor: 25.083
Authors: Annika Bergquist; Anders Ekbom; Rolf Olsson; Dan Kornfeldt; Lars Lööf; Ake Danielsson; Rolf Hultcrantz; Stefan Lindgren; Hanne Prytz; Hanna Sandberg-Gertzén; Sven Almer; Fredrik Granath; Ulrika Broomé Journal: J Hepatol Date: 2002-03 Impact factor: 25.083
Authors: Shahid A Khan; Simon D Taylor-Robinson; Mireille B Toledano; Angus Beck; Paul Elliott; Howard C Thomas Journal: J Hepatol Date: 2002-12 Impact factor: 25.083
Authors: Jan Harder; Oliver Kummer; Manfred Olschewski; Florian Otto; Hubert Erich Blum; Oliver Opitz Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-10 Impact factor: 4.254
Authors: John E Eaton; Christopher L Welle; Zeinab Bakhshi; Shannon P Sheedy; Ilkay S Idilman; Gregory J Gores; Charles B Rosen; Julie K Heimbach; Timucin Taner; Denise M Harnois; Keith D Lindor; Nicholas F LaRusso; Andrea A Gossard; Konstantinos N Lazaridis; Sudhakar K Venkatesh Journal: Hepatology Date: 2021-04-19 Impact factor: 17.425
Authors: Felix Hahn; Lukas Müller; Florian Jungmann; Aline Mähringer-Kunz; Yasemin Tanyildizi; Christoph Düber; Peter R Galle; Arndt Weinmann; Roman Kloeckner Journal: J Cancer Res Clin Oncol Date: 2020-03-30 Impact factor: 4.553
Authors: T Sugiura; K Uesaka; Y Okamura; T Ito; Y Yamamoto; R Ashida; K Ohgi; S Otsuka; M Nakagawa; T Aramaki; K Asakura Journal: BJS Open Date: 2021-07-06